Candriam SCA’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-702,631
| Closed | -$4.24M | – | 805 |
|
|
2019
Q4 | $4.24M | Sell |
702,631
-262,369
| -27% | -$1.52M | 0.05% | 408 |
|
|
2019
Q3 | $3.47M | Buy |
965,000
+240,000
| +33% | +$925K | 0.05% | 395 |
|
|
2019
Q2 | $1.93M | Hold |
725,000
| – | – | 0.02% | 527 |
|
|
2019
Q1 | $2.15M | Hold |
725,000
| – | – | 0.03% | 482 |
|
|
2018
Q4 | $1.15M | Buy |
725,000
+75,000
| +12% | +$212K | 0.02% | 562 |
|
|
2018
Q3 | $2.39M | Hold |
650,000
| – | – | 0.03% | 464 |
|
|
2018
Q2 | $1.84M | Hold |
650,000
| – | – | 0.03% | 505 |
|
|
2018
Q1 | $2.41M | Buy |
650,000
+215,000
| +49% | +$704K | 0.04% | 435 |
|
|
2017
Q4 | $1.25M | Sell |
435,000
-5,000
| -1% | -$18.2K | 0.02% | 544 |
|
|
2017
Q3 | $1.98M | Buy |
+440,000
| New | +$1.95M | 0.03% | 463 |
|
|
2016
Q3 | – | Sell |
-148,000
| Closed | -$1.15M | – | 686 |
|
|
2016
Q2 | $1.15M | Sell |
148,000
-137,000
| -48% | -$1.18M | 0.03% | 412 |
|
|
2016
Q1 | $2.19M | Sell |
285,000
-59,300
| -17% | -$434K | 0.05% | 310 |
|
|
2015
Q4 | $3.71M | Hold |
344,300
| – | – | 0.1% | 218 |
|
|
2015
Q3 | $2.38M | Sell |
344,300
-35,700
| -9% | -$291K | 0.06% | 313 |
|
|
2015
Q2 | $3.37M | Buy |
380,000
+25,000
| +7% | +$236K | 0.07% | 294 |
|
|
2015
Q1 | $3.5M | Buy |
355,000
+50,000
| +16% | +$624K | 0.07% | 312 |
|
|
2014
Q4 | $3.74M | Buy |
+305,000
| New | +$3.72M | 0.08% | 283 |
|
Candriam SCA's ACHN Position: Q1 2020 in Review
Candriam SCA sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 702,631 shares — an estimated $4.24M sold.
Candriam SCA first reported a position in ACHN in Q4 2014 and held it in 17 quarters. The position peaked at $4.24M in Q4 2019. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- Candriam SCA reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- Candriam SCA sold 702,631 Achillion Pharmaceuticals shares in Q1 2020, an estimated $4.24M.
- Candriam SCA first reported a position in Achillion Pharmaceuticals in Q4 2014 and held it in 17 quarters.
- Candriam SCA's Achillion Pharmaceuticals position peaked at $4.24M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on Candriam SCA's 13F filing for Q1 2020, filed 26 May 2020.